Eindhoven-based Xeltis, a clinical-stage medtech company, announced on Tuesday, February 21, that it has secured €32M in a Series D2 equity fundraising.
The investment came from a syndicate of current and new investors, including Grand Pharma, DaVita Venture Group, EQT Life Sciences, Invest-NL, and other international investors.
Xeltis says it will use the proceeds to advance its crucial clinical programmes into pivotal trials to give patients an advanced restorative cardiovascular device.
“The strategic support of Grand Pharma and DaVita alongside our existing investor base represents a strong validation of our technology and potential to transform the landscape of cardiovascular surgery. We remain focused on progressing our aXess clinical trials, as well as exploring our next steps in other indications,” comments Eliane Schutte, CEO of Xeltis.